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Abstract
Background: Type I hexokinase (HK-I) constitutes the predominant form of the enzyme in the
brain, a major portion of which is associated with the outer mitochondrial membrane involving two
sets of binding sites. In addition to the glucose-6-phosphate (G6P)-sensitive site (Type A), the
enzyme is bound on a second set of sites (Type B) which are, while insensitive to G6P, totally
releasable by use of high concentrations of chaotropic salts such as KSCN. Results obtained on
release of HK-I from these "sites" suggested the possibility for the existence of distinct populations
of the bound enzyme, differing in susceptibility to release by G6P.
Results: In the present study, the sensitivity of HK-I toward release by G6P (2 mM) and a low
concentration of KSCN (45 mM) was investigated using rat brain, bovine brain and human brain
mitochondria. Partial release from the G6P-insensitive site occurred without disruption of the
mitochondrial membrane as a whole and as related to HK-I binding to the G6P-sensitive site.
While, as expected, the sequential regime release-rebinding-release was observed on site A, no
rebinding was detectable on site B, pre-treated with 45 mM KSCN. Also, no binding was detectable
on mitochondria upon blocking site A for HK-I binding utilizing dicyclohexylcarbodiimide (DCCD),
followed by subsequent treatment with KSCN. These observations while confirmed the previously-
published results on the overall properties of the two sites, demonstrated for the first time that
the reversible association of the enzyme on mitochondria is uniquely related to the Type A site.
Conclusion: Use of very low concentrations of KSCN at about 10% of the level previously
reported to cause total release of HK-I from the G6P- insensitive site, caused partial release from
this site in a reproducible manner. In contrast to site A, no rebinding of the enzyme takes place on
site B, suggesting that site A is 'the only physiologically-important site in relation to the release-
rebinding of the enzyme which occur in response to the energy requirements of the brain. Based
on the results presented, a possible physiological role for distribution of the enzyme between the
two sites on the mitochondrion is proposed.
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Background
The type I isoenzyme of mammalian hexokinase (HK-I;
ATP: D-hexose-6-phoshotransferase, EC 2.7.1.1) binds
reversibly to the outer mitochondrial membrane, a proc-
ess which has been suggested to be involved in regulation
of its activity [1]. Accordingly, in a variety of situations, it
has been observed, that the rate of glycolysis depends on
the level of hexokinase bound to mitochondria [2]. An
outer mitochondrial membrane protein responsible for
specific binding of HK- I was first isolated by Felgner et al.
[3]. Later, this protein was shown to be identical to mito-
chondrial porin [4] also called voltage-dependent anion
channel (VDAC). The protein has been shown to form the
channel through which metabolites enter and exit the
mitochondrion. It is by this mechanism that the enzyme
gains preferential access to mitochondrially-generated
ATP, with decreased susceptibility to product inhibition
and proteolytic digestion. Thus definition of the molecu-
lar basis of the interaction of HK-I and the outer mito-
chondrial membrane is directly relevant to our
understanding of regulation of enzyme activity. A 15-
amino acid hydrophobic segment of HK-I is the docking
domain necessary and sufficient for binding to mitochon-
dria [5]. Treatment of intact mitochondria with dicy-
clohexylcarbodiimide (DCCD) was found to produce a
large steric hindrance to the interaction between this N-
terminal segment and the corresponding region in porin,
thereby resulting in inhibition of binding [6]. It has been
suggested that changes in HK-I distribution may consti-
tute a target for a new therapeutic approach for malignant
tumors [7].
The distribution of the enzyme between mitochondrially
bound and dissociated forms has been found to be influ-
enced by the level of certain metabolites, especially G6P
[8]. In addition to this, a second type of binding site has
been shown to be present in mammalian mitochondria
[9], including normal and tumoral human brain tissues
[10], which is insensitive to G6P but is released by chao-
tropic salts such as KSCN [9]. Results obtained on release
of HK-I from these "sites" suggested the possibility for
existence of distinct populations of the bound enzyme in
various species, differing in susceptibility to release by
G6P [9].
In the present study, the sensitivity of HK-I toward release
by 2 mM G6P (Type A sites) and 45 mM KSCN (Type B
sites) has been investigated. Preliminary experiments
using rat brain and bovine brain mitochondria indicated
that this low concentration of the chaotropic salt is capa-
ble of causing partial release of the enzyme from the G6P-
insensitive sites (B-HK-I) without disruption of the mito-
chondrial membrane. Rebinding experiments performed
using intact and DCCD-blocked mitochondria, treated
sequentially with G6P and KSCN, suggested that the
reversible association of the enzyme on mitochondria
may be uniquely related to the Type A sites. Use of a low
concentration of KSCN appears to have provided a new
tool in furnishing information on the properties of the
two types of binding sites of HK-I on the mitochondria.
Results
Solubilization of mitochondrial hexokinase by G6P and 
KSCN
Sequential treatment of rat, bovine and human brain
mitochondria with 2 mM G6P and 45 mM KSCN was car-
ried out. The extent of release by use of the low concentra-
tions of KSCN was limited but significant and
reproducible in all the three cases. Treatment of intact or
KSCN- treated bovine or human brain mitochondria with
G6P provided similar results, based on units of releasable
activity (Table 1). Therefore, it appears that use of 45 mM
KSCN does not affect release of the enzyme from Site A of
these mitochondria, which occurs by treatment of intact
mitochondria with G6P. In rat brain mitochondria, how-
ever, presumably due to the presence of large proportion
of HK at site A, some of the enzyme at this site is suscepti-
ble to release by low concentration of KSCN (Table 1).
As expected, the extents of release from intact mitochon-
dria, or G6P-treated mitochondria on which HK-I was
Table 1: Solubilization of mitochondrially- bound hexokinase of rat, bovine and human brain tissues' mitochondria by sequential 
treatment with G6P and KSCN
Treatment Rat Bovine human
% Release First, with G6P 80 ± 2.1 46 ± 0.8 55 ± 1.8
Second, with KSCN 10 ± 0.8 9.2 ± 0.75 7.7 ± 1.85
First, with KSCN 33.4 ± 0.8 8.8 ± 0.3 5.1 ± 0.075
Second, with G6P 51 ± 7.6 44.2 ± 4.3 53 ± 0.95
Solubilization of hexokinase by G6P (2 mM) and KSCN (45 mM) was determined as noted under Methods. The remaining activity of HK on G6P 
treated mitochondria (e.g. for rat; 20%), was subject to release by KSCN. Ten percent of the enzyme activity could be released in this process. Total 
activity which could be released in the two steps, never exceed 100%. Values shown are means ± SE of at least 3 determinations.BMC Biochemistry 2007, 8:20 http://www.biomedcentral.com/1471-2091/8/20
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rebound, were almost identical, when subsequent treat-
ment with G6P was carried out.
Rebinding of hexokinase on mitochondria
It was expected that treatment by KSCN of mitochondria
pre-treated by G6P would enhance the extent of rebinding
by providing additional binding sites. However, this was
not what was observed and repeated experiments indi-
cated that rebinding on these mitochondria was slightly
lower, if any difference were to be suggested from the data
(Table 2). The most unexpected results were obtained
when rebinding experiments were performed on mito-
chondria treated with KSCN, prior to treatment with G6P.
As indicated (Table 2), no rebinding was detected on these
mitochondria. Subsequent treatment of these mitochon-
dria (KSCN-treated) with G6P followed by rebinding
experiments indicated somewhat less but similar extents
of binding, as compared with the situation in which they
were pre-treated with G6P, alone or with G6P followed by
KSCN (Table 2). These experiments indicate that site A
retains its overall capacity for binding after treatment with
45 mM KSCN and, taken together, suggest a distinct role
for the chaotropic salt, at the low concentration utilized,
in releasing the enzyme from site B. This somewhat unex-
pected effect of low KSCN, combined with other experi-
mental finding suggest the proposition that the observed
rebinding is related only to the Type A site. Treatment of
rat liver mitochondria with up to 60 mM concentration of
KSCN provided exactly the same extent of binding (Table
3) further supporting the view that loss of binding (for rat
and bovine brain mitochondria, Table 2) was not due to
the effect of the chaotropic salt on the mitochondrial
membrane.
Another approach taken in these rebinding experiments
involved treatment of mitochondria with DCCD, which
has been previously shown to block site A for HK-I bind-
ing [6]. Results presented in Table 4 report on hexokinase
binding experiments using initial treatment with G6P fol-
lowed by blockage with DCCD and, finally, treatment
with KSCN. No binding could be detected, thus support-
ing the proposition that process of release-rebinding of
HK-I on mitochondria is uniquely related to site A.
Discussion
Over 80% of HK-1 activity in the brain is associated with
mitochondria [11]. This interaction has been suggested to
play a central role in regulation of HK-I activity [12] and
to involve two types of sites [9,13,14]. In this model,
which is one of several defining association of the enzyme
to the outer mitochondrial membrane, the Type A sites are
defined as mitochondrial sites from which the enzyme is
released by the action of G6P, while the Type B sites are
those at which HK-I remains bound even in the presence
of G6P [11]. The latter has been shown to be affected by
chaotropic salts such as KSCN [9]. HK G6P (A-HK-I) and
HKKSCN (B-HK-I) represent HK-I released by treatment of
mitochondria with G6P and by subsequent treatment
with KSCN, and appear to be identical [9]. Results
obtained on release of HK-I from these sites on mitochon-
dria of various species suggested the possibility for the
existence of distinct populations of the bound enzyme on
the same mitochondria, differing in susceptibility to
release by G6P. Furthermore, the two sites have been pro-
posed to be located in membrane domains of different
lipid composition, with the G6P-sensitive sites being in
those enriched in acidic phospholipids [13]. Interaction
of hexokinase with a number of subcellular (non-mito-
chondrial) structures have been found to take place in a
G6P-independent manner [see [15] and references
therein], further implying that binding of the enzyme to
biological structures may occur in this manner.
In the present study, 2 mM G6P and 45 mM KSCN, were
used to release HK-I from the two binding sites of rat,
bovine and human brain mitochondria. The decision on
the use of 45 mM KSCN which has established an impor-
tant aspect of the present study, was based on the fact that
the chaotropic salt, at the concentration utilized, did not
cause any detectable disruption of the outer rat brain
mitochondrial membrane, while, at the same time, caused
measurable and reproducible release of HK-I. At concen-
trations higher than 55 mM, clear loss of mitochondrial
integrity became obvious, based on activity determination
of marker enzymes, as outlined in Methods. Also, KSCN
at concentrations up to 60 mM, did not alter the binding
capacity of rat liver mitochondria for HK-I (see Methods
and Table 3). Regarding the effectiveness of a chaotropic
salt such as KSCN in causing release of B-HK-I, it is intrigu-
ing that the partitioning of mitochondrially-bound hex-
okinase into hydrophobic (Triton ×-114) phase may be
correlated with the proportion of the Type B sites [11].
This is apparently related to the type of the phospholipids
Table 2: Rebinding of rat brain hexokinase to rat and bovine 
brain mitochondria
Treatment Rat Bovine
% Rebinding First, with G6P 61 ± 3.9 52 ± 1.4
Second, with KSCN 57 ± 1.9 48 ± 1.4
First, with KSCN N.D N.D
Second, with G6P 44.5 ± 3.5 36.5 ± 2.1
Rebinding of 0.016 U of rat brain hexokinase to mitochondria 
previously treated sequentially with 2 mM G6P/45 mM KSCN, and in 
the reverse order, was carried out. An amount of mitochondrial 
suspension corresponding to 1 mg protein was used in a total volume 
of 500 µL in all cases. Values shown are means ± S.E. of at least 3 
determinations. Further details are described in Methods section. 
N.D.; not detectableBMC Biochemistry 2007, 8:20 http://www.biomedcentral.com/1471-2091/8/20
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present in membrane domains in which B-HK-I is located
[11].
The most significant aspect of the present study is reflected
by the fact that no rebinding of HK-I was detectable on
mitochondria pre-treated with 45 mM KSCN (Table 2) in
spite of measurable release of the enzyme (Table 1).
Although use of a low concentration of the chaotropic salt
served an important purpose in that it caused release
while avoiding disruption of the mitochondrial mem-
brane, the extent of release was not as high as one would
have wished. Therefore, attempts were made toward
enhancing release, while at the same time, keeping the
integrity of the membrane structure. Amongst these strat-
egies, use of a lower temperature for release by 45 mM
KSCN (10°C instead of 30°C, based on the observations
reported in reference [16]), and a mixture of KSCN and
KCl (each at 22.5 mM concentration at 10°C), increased
release from the usual 17% to 30% and 45%, respectively.
Again, no binding could be detected. It is also noteworthy
that use of MgCl2, at concentrations up to 6 mM resulted
in no detectable rebinding, as observed in its absence
(compare with the effectiveness of MgCl2 related to HK-I
binding on site A, see, for example, [17]). Longer incuba-
tion times in the presence of KSCN did not result in
greater release, suggesting that the KSCN-mediated proc-
ess is at equilibrium.
The indication that site B is intrinsically incapable of
rebinding was supported by repeating binding experi-
ments with DCCD-blocked mitochondria following the
procedure previously reported for mitochondria isolated
from rat liver and hepatoma cells [6].
The fact that rebinding does not take place on site B would
support the proposition that site A is the only physiologi-
cally-important site in relation to the release -rebinding of
the enzyme shown to occur in response to the energy need
of the brain [18]. This would not be surprising since G6P
is probably the most important metabolite for HK-I in
relation to structure-function of this allosteric protein in
the brain.
In a study involving treatment of rat brain mitochondria
with digitonin, two porin populations were suggested to
exist in different membrane environments with regard to
cholesterol [19]. One of these is thought to be located in
a membrane environment relatively free of cholesterol
(digitonin-resistant) and the other in a more cholesterol-
rich domain (digitonin-solubilized). Furthermore, it has
been suggested [19] that in rat brain mitochondria, hex-
okinase is predominantly located in relatively cholesterol-
free domain. An increase in the level of cholesterol in bio-
logical membranes has been shown to coincide with fun-
damental changes including enhancement of rigidity and
condensation [see for example [20] and references
therein]. It may therefore be suggested that only in choles-
terol-free domains, does the membrane have the required
flexibility allowing for repeated release and rebinding of
the enzyme at contact sites, controlled by the level of
available G6P. Moreover, electrostatic interactions, an
important component of this association [13], would
probably be better facilitated at these sites.
If this is indeed the case, then what could be suggested as
the reason for the presence of B-HK-I at such high propor-
tions in bovine and human brain mitochondria [9]?
Table 4: Use of DCCD in release rebinding experiments involving rat brain HK and rat, bovine and human brain mitochondria
S t e p s 1234
Process %Release (with G6P) Blocking (with DCCD) %Release (with KSCN) Rebinding
Rat 81 ± 3 Yes 30 ± 2.1 N.D.
Bovine 38 ± 2.7 Yes 19 ± 1.7 N.D.
Human 48.5 ± 3.5 Yes 17.5 ± 2.5 N.D.
Mitochondria from three species were subjected to HK release by G6P (2 mM) in the first step. Then, the exposed binding sites of G6P – treated 
mitochondria were blocked by DCCD (0.01 mM). At the third step, the remaining HK activity on this DCCD-treated mitochondria was released 
with 45 mM KSCN. Finally the depleted (both sites) blocked (G6P-sensitive sites) mitochondria were used for the rebinding process, according to 
details described under Methods. N.D.; not detectable
Table 3: Effect of KSCN at various concentrations on rebinding capacity of rat liver mitochondria
KSCN(mM) 0 35 45 55 65
Rebinding (%) 50.2 ± 2.2 49 ± 1.76 49 ± 0.75 50 ± 2.1 49.5 ± 1.4
Rat liver mitochondria were treated with KSCN at various concentrations. 0.1 unit of hexokinase was rebound on 4.5 mg mitochondria at total 
volume of 1.00 ml and incubated for 30 minute on ice in the presence of MgCl2 (3 mM). The percentage of rebound enzyme was evaluated by the 
activity rebounded on mitochondria which was assayed according to Methods.BMC Biochemistry 2007, 8:20 http://www.biomedcentral.com/1471-2091/8/20
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Could it act as a reservoir providing "rate-limiting" A-HK-
I, when in need? Accordingly, could it be suggested that A-
HK-I being at limiting proportions in the human brain
(about 20%) may exert a greater physiological role as
compared to the situation (in rat brain mitochondria)
where it is present in relative abundance (about 80%)?
This is not inconceivable since redistribution of A-HK-I
under certain experimental conditions has suggested a
dynamic relationship between the Type A and the Type B
sites [11], and the conformation of B-HK-I may alter upon
removal of A-HK-I [14]. Furthermore, this specific obser-
vation is in line with our general understanding of the
dynamics of biological membranes.
Based on the results presented here and the excellent ear-
lier work of Wilson and co-workers [see for example [14]
and references therein], it appears that the higher propor-
tion of B-HK-I in the bovine and human brains, as com-
pared to other mammalian sources, is not by coincidence.
But, quite the contrary, it probably serves an important
purpose in the overall context of the physiological role the
association of hexokinase is thought to play in relation to
regulation of glucose metabolism in the brain.
Conclusion
In conclusion, the results presented demonstrate that the
reversible association of type I hexokinase to the outer
mitochondrial membrane is uniquely related to Type A
site on the mitochondrion. Although a clear explanation
for the role of HK bound to the type B sites cannot be
offered with certainty, it can be suggested that the B sites
may act as a reservoir of HK, furnishing the enzyme to the
A sites when needed under high energy demands of the
cell. More work would be required to substantiate this
proposition.
Methods
All biochemicals were obtained from Sigma Chemical Co.
(St. Louis, MO, USA). Other chemicals were of reagent
grade and products of Merck (Darmstadt, Germany). Rat
brains were obtained from adult NMRI rats. Animals were
killed by decapitation and the brains were rapidly
removed and frozen immediately in liquid air where they
were stored until use. Bovine brain was prepared from
local slaughter house, and transferred to the lab in liquid
air. Human normal brain tissue was obtained from neuro-
surgery department of a local hospital as biopsy specimen
and transferred to the lab in liquid air, where they were
stored until use.
Rat, bovine and human brain mitochondria were pre-
pared as previously described [9]. Rat liver mitochondria
were isolated according to Bustamante et al. [21]. Protein
assay was done according to M-Katzenellenbogen et al.
[22], and hexokinase activity was routinely determined as
described previously [10]. Solubilization of mitochondri-
ally-bound HK, determination of percentage release, and
rebinding of the released (and re-concentrated) enzyme
were carried out exactly as described by Kabir and Wilson
[9]. The amount of solubilized activity is expressed as a
percentage of the total activity in the mitochondrial frac-
tion. In these experiments, the mitochondrial suspension
was subjected to release with G6P (2 mM, pH 8.5) and
after this step of solubilization, the resuspended pellet, in
the same initial volume, was treated with 45 mM KSCN
(pH 8.5, at 30°C, except otherwise indicated). The incu-
bation time was the same as that used for G6P-induced
solubilization, providing similar experimental conditions
for the two releasing factors. In related experiments, this
sequential process of release was reversed. Mitochondrial
membrane integrity was confirmed by determination of
the specific activities of marker enzymes: (malate dehy-
drogenase [23], glutamate dehydrogenase [24], rotenone-
insensitive cytochrome c oxidase [25], citrate synthase
[26] and adenylate kinase [27]) before and after treatment
with KSCN (45 mM). Rat liver mitochondria were treated
with KSCN at the chosen concentrations, and rebinding of
rat brain HK-I on these preparations was performed as a
control experiment.
Rebinding of HK was carried out after preliminary experi-
ments for determination of appropriate ratios of HK:
mitochondria. Data presented by Xie and Wilson were
used as a guideline [28], thereby making sure that suffi-
cient amounts of the enzyme was present for binding to
any available sites on the mitochondria. To minimize the
presence of any proteolytically-cleaved HK in these exper-
iments, freshly-released (by G6P treatment) and concen-
trated enzyme was used. In brief, the G6P or KSCN-treated
mitochondria (1 mg protein) were subjected to rebinding
of released and concentrated enzyme (0.016 U) in total
volume of 0.5 ml. Incubation carried out for 30 min on
ice (in the presence of 2 mM MgCl2) was followed by cen-
trifugation for 10 min using a microfuge. The pellet was
resuspended in 0.5 ml of 0.25 M sucrose and assayed for
bound hexokinase activity, or was subject to another
release/rebinding regimen after washing (twice) with the
same volume of 0.25 M sucrose. Reproducibility of the
data presented in this manuscript was confirmed by
repeating the experiments at least three times. Chemical
modification by DCCD was performed by following a
procedure described previously [6]. The observed pattern
of dependency of loss of HK-I binding on the concentra-
tion of DCCD utilized, was found to be similar to those
reported for mitochondria isolated from rat liver and
hepatoma cells [6]. Routinely, a portion of these mito-
chondria was incubated for 15 min at room temperature
with 0.01 mM DCCD (added from a 1 mM stock solution
in methanol). Initial experiments (data not shown) indi-
cated that DCCD at this concentration was maximallyPublish with BioMed Central    and   every 
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effective in blocking HK rebinding. The mitochondria
were washed once with 0.25 M sucrose and used for the
binding experiments. Control mitochondria were sub-
jected to the same regimen except that pure methanol was
used in place of the stock DCCD solution. DCCD did not
affect hexokinase activity at the concentration utilized. Its
effect on prevention of rebinding was performed accord-
ing to Kabir and Wilson [9]. Briefly, mitochondria were
subjected to HK release by G6P (2 mM). The pellet was
resuspended in 0.25 M sucrose at 4 mg/ml (referred to as
untreated).
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